IP Library Granted Patent US 11,279,972
Granted Patent B2
US 11,279,972 · App. 16/245,737 · Granted Mar 22, 2022

Enhanced adaptor ligation

Inventors: Vladimir Makarov (Ann Arbor, MI); Julie Laliberte (Ypsilanti, MI)
Assignee: SWIFT BIOSCIENCES, INC.
C12Q1/6855C12N9/1252C12N9/93C12Q1/6806C12Y207/07007C12Y605/01001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,279,972
App. No.
16/245,737
Granted
Mar 22, 2022
Kind
B2
Abstract

The present disclosure describes a method of adapter ligation to the ends of fragmented double-stranded DNA molecules.

Claims (15)

1. A method of producing a processed substrate molecule, the method comprising:

(i) adding a first polynucleotide and a ligase to a sample comprising a substrate nucleic acid molecule, wherein the substrate nucleic acid molecule is at least partially double-stranded and has a phosphate at its 5′ ends, wherein the first polynucleotide comprises oligonucleotide A, oligonucleotide B, and a double-stranded portion, wherein the double-stranded portion comprises oligonucleotide A hybridized to oligonucleotide B, wherein oligonucleotide A lacks a 5′ phosphate and comprises a base that is susceptible to degradation;

(ii) incubating the sample under conditions sufficient to ligate oligonucleotide B to the 5′ ends of the substrate nucleic acid molecule;

(iii) adding to the sample a second polynucleotide, an enzyme capable of degrading oligonucleotide A, and an enzyme having 5′ flap endonuclease cleavage activity, wherein the second polynucleotide lacks a 5′ phosphate, has a 3′ portion capable of annealing to a 3′ portion of oligonucleotide B, and comprises a 5′ portion comprising at least one base, wherein said 5′ portion is not complementary to oligonucleotide B and forms a 5′ flap that does not anneal to oligonucleotide B upon annealing of the 3′ portion of the second polynucleotide with the 3′ portion of oligonucleotide B; and then

(iv) incubating the sample under conditions sufficient to (i) promote degradation of oligonucleotide A by the enzyme capable of degrading oligonucleotide A, (ii) promote annealing of the 3′ portion of the second polynucleotide to the 3′ portion oligonucleotide B (iii) allow the enzyme having 5′ flap endonuclease cleavage activity to excise the 5′ portion of the second polynucleotide to remove the 5′ flap, and (iv) allow the ligase to act on the substrate nucleic acid molecule in order to add the second polynucleotide to the 3′ ends of the substrate nucleic acid molecule thereby forming the processed substrate molecule.

2. The method of claim 1 , wherein the substrate nucleic acid molecule is genomic DNA.

3. The method of claim 2 , wherein the genomic DNA is eukaryotic.

4. The method of claim 1 , wherein the substrate nucleic acid molecule is synthetic and is selected from the group consisting of cDNA, DNA produced by whole genome amplification, primer extension products comprising at least one double-stranded terminus, and a PCR amplicon.

5. The method of claim 2 , wherein the genomic DNA is prokaryotic.

6. The method of claim 1 , further comprising a purification step after step (ii), wherein the purification removes any unused first polynucleotide.

7. The method of claim 6 , further comprising adding ligase to the sample in step (iii).

8. The method of claim 1 , wherein the enzyme having 5′ flap endonuclease cleavage activity is Taq DNA polymerase.

9. The method of claim 2 , wherein the substrate nucleic acid molecule is synthetic and is selected from the group consisting of cDNA, DNA produced by whole genome amplification, primer extension products comprising at least one double-stranded terminus, and a PCR amplicon.

10. The method of claim 3 , wherein the substrate nucleic acid molecule is synthetic and is selected from the group consisting of cDNA, DNA produced by whole genome amplification, primer extension products comprising at least one double-stranded terminus, and a PCR amplicon.

11. The method of claim 5 , wherein the substrate nucleic acid molecule is synthetic and is selected from the group consisting of cDNA, DNA produced by whole genome amplification, primer extension products comprising at least one double-stranded terminus, and a PCR amplicon.

Assignments (2)
MERGER Recorded Apr 15, 2022
From: SWIFT BIOSCIENCES, INC.
To: INTEGRATED DNA TECHNOLOGIES, INC.
Reel/Frame 059606/0848 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2020
From: MAKAROV, VLADIMIR; LALIBERTE, JULIE
To: SWIFT BIOSCIENCES, INC.
Reel/Frame 054727/0866 →
Continuity (4)
Continuation 15122980
Provisional Application 61952854 · Mar 13, 2014
Provisional Application 61947235 · Mar 3, 2014
Related Publication 20190218605A1 · Jul 18, 2019